Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and Crescent Biopharma, Inc. have announced a strategic partnership aimed at advancing the development and commercialization of innovative oncology therapeutics, specifically focusing on novel combinations. This collaboration centers on Crescent’s CR-001, a PD-1 x VEGF bispecific antibody, and Kelun-Biotech’s SKB105, an integrin beta-6-directed antibody-drug conjugate (ADC), both targeting solid tumors and set to enter Phase 1/2 clinical trials in early 2026.
The partnership grants Crescent exclusive rights to develop and commercialize CR-001 in Greater China, while Kelun-Biotech retains similar rights for SKB105 in the U.S., Europe, and other markets. This arrangement not only facilitates the independent development of both candidates but also allows for the exploration of combination therapies, potentially enhancing treatment efficacy across various tumor types.
Financially, the collaboration involves significant upfront payments and milestone opportunities, with Kelun-Biotech receiving $80 million from Crescent and being eligible for up to $1.25 billion in milestones. This strategic alliance not only expands both companies’ oncology pipelines but also leverages their respective strengths to expedite clinical development while adhering to stringent global standards, ultimately aiming to improve patient outcomes in cancer care.
Start your 7-day trial and see what the database can do →
